CMS Jumps Out Ahead Of FDA With Transcatheter Valve Coverage Analysis

Edwards Lifesciences is still waiting on an approval decision from FDA on the first indication for its Sapien transcatheter aortic heart valve replacement, but CMS has decided not to wait.